Latest Breaking News On - க்கு நிலவியல் - Page 1 : comparemela.com

Global  , by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is expected to be valued at US$  35.8 million in 2018 and is estimated to exhibit a CAGR of  55.4% over the forecast period (2018-2026),  as highlighted in a new report published by Coherent Market Insights. The increasing launches and regulatory approval of novel therapies indicated for the treatment of transthyretin amyloidosis are expected to drive growth of the market over the forecast period. For instance, in October 2018, Alnylam Pharmaceuticals, Inc. launched ONPATTRO (patisiran) in Germany. The drug is indicated for the treatment of hereditary transt

United statesUnited kingdomSouth africaSouth koreaAsia pacificTafamidis vyndaqelGlaxosmithkline plcProthena corporation plcIonis pharmaceuticals incAlnylam pharmaceuticals incPfizer incResearch objectivesAkcea therapeutics incPorter five forces analysisEidos therapeutics incCompany overview